Alp S, et al. - In the present study, the researchers sought to characterize the clinical features, administered antifungal agents, outcomes of individuals with rare yeasts other than Candida (RY‐OTC) fungaemia, and to identify the antifungal susceptibility profiles of the isolates. Between January‐2001 and December‐2018, RY‐OTC fungaemia have been retrospectively evaluated. Nineteen individuals with fungaemia were identified due to 20 RY‐OTC (8 Trichosporon asahii, 4 Cryptococcus neoformans, 4 Saprochaete capitata, 3 Rhodotorula mucilaginosa, 1 Trichosporon mucoides) with an incidence of 2.2% among 859 fungaemia episodes. The most common (42%) underlying disorder was haematological malignancy. The drugs of choice for the initial treatment of breakthrough fungaemia were amphotericin B, fluconazole or voriconazole. The most common empirical treatment was an echinocandin (50%), followed by fluconazole (42%) and amphotericin B (8%) among patients without previous exposure to antifungals. Data reported that overall mortality was 47%. Among patients receiving echinocandins, worse outcome was most common. Early identification of RY‐OTC and knowledge of its susceptibility patterns remain crucial in initial treatment pending isolate susceptibility data.